3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
13
Rectal Neoplasms
5
Neoplasm Metastasis
4
Cholangiocarcinoma
4
Stomach Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Hepatocellular
3
Biliary Tract Neoplasms
3
Adenocarcinoma Of Esophagus
3
Ovarian Neoplasms
2
Neoplasms
2
Gastrointestinal Neoplasms
2
Gallbladder Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Recurrence
1
Pathologic Complete Response
1
Lung Neoplasms
1
Endometrial Neoplasms
1
Disease Progression
1
Central Nervous System Neoplasms
1
Carcinoma, Basal Cell
1
Breast Neoplasms
1
Bile Duct Neoplasms
1
Advanced Rectal Cancer
1
Adenocarcinoma of the Lower Rectum
1
Adenocarcinoma
1
Interventions
Gemcitabine
6
Cisplatin
6
pembrolizumab
3
durvalumab
3
Oxaliplatin
3
tivozanib
2
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
trametinib
1
tislelizumab
1
olaparib
1
atezolizumab
1
Yttrium-90
1
Stents
1
Radiosurgery
1
Nivolumab
1
Leucovorin
1
Ipilimumab
1
Folfox protocol
1
Fluorouracil
1
Floxuridine
1
Dexamethasone
1
Capecitabine
1
CTLA-4 Antigen
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bile Duct Neoplasms
×
Folfox protocol
×
90 days
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts